IL315905A - 5-METHOXY-N.N-DIMETHYLTRYPTamine for the treatment of psychomotor retardation - Google Patents
5-METHOXY-N.N-DIMETHYLTRYPTamine for the treatment of psychomotor retardationInfo
- Publication number
- IL315905A IL315905A IL315905A IL31590524A IL315905A IL 315905 A IL315905 A IL 315905A IL 315905 A IL315905 A IL 315905A IL 31590524 A IL31590524 A IL 31590524A IL 315905 A IL315905 A IL 315905A
- Authority
- IL
- Israel
- Prior art keywords
- dimethyltryptamine
- methoxy
- treatment
- psychomotor retardation
- psychomotor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22000084 | 2022-03-27 | ||
| EP22000085 | 2022-03-27 | ||
| EP23153996 | 2023-01-30 | ||
| EP23154014 | 2023-01-30 | ||
| PCT/EP2023/057878 WO2023186831A1 (en) | 2022-03-27 | 2023-03-27 | 5-methoxy-n.n-dimethyltryptamine for the treatment of psychomotor retardation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL315905A true IL315905A (en) | 2024-11-01 |
Family
ID=86007029
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315905A IL315905A (en) | 2022-03-27 | 2023-03-27 | 5-METHOXY-N.N-DIMETHYLTRYPTamine for the treatment of psychomotor retardation |
| IL315892A IL315892A (en) | 2022-03-27 | 2023-03-27 | 5-MEO-DTM for the treatment of bipolar disorder |
| IL315904A IL315904A (en) | 2022-03-27 | 2023-03-27 | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of social/emotional withdrawal or withdrawal |
| IL315901A IL315901A (en) | 2022-03-27 | 2023-03-27 | 5-MEO-DMT for use in the treatment of sleep disorders |
| IL315903A IL315903A (en) | 2022-03-27 | 2023-03-27 | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of cognitive dysfunction |
| IL315900A IL315900A (en) | 2022-03-27 | 2023-03-27 | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of anxiety |
| IL315895A IL315895A (en) | 2022-03-27 | 2023-03-27 | Postpartum depression treatment |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315892A IL315892A (en) | 2022-03-27 | 2023-03-27 | 5-MEO-DTM for the treatment of bipolar disorder |
| IL315904A IL315904A (en) | 2022-03-27 | 2023-03-27 | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of social/emotional withdrawal or withdrawal |
| IL315901A IL315901A (en) | 2022-03-27 | 2023-03-27 | 5-MEO-DMT for use in the treatment of sleep disorders |
| IL315903A IL315903A (en) | 2022-03-27 | 2023-03-27 | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of cognitive dysfunction |
| IL315900A IL315900A (en) | 2022-03-27 | 2023-03-27 | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of anxiety |
| IL315895A IL315895A (en) | 2022-03-27 | 2023-03-27 | Postpartum depression treatment |
Country Status (9)
| Country | Link |
|---|---|
| US (10) | US20250213528A1 (enExample) |
| EP (8) | EP4499072A1 (enExample) |
| JP (7) | JP2025512866A (enExample) |
| KR (7) | KR20250005177A (enExample) |
| CN (5) | CN119255799A (enExample) |
| AU (7) | AU2023244447A1 (enExample) |
| CA (7) | CA3255709A1 (enExample) |
| IL (7) | IL315905A (enExample) |
| WO (9) | WO2023186831A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3753923A1 (en) | 2019-06-19 | 2020-12-23 | GH Research Limited | Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent |
| US12534441B2 (en) | 2021-01-15 | 2026-01-27 | Beckley Psytech Limited | Tryptamine analogues |
| WO2022153266A1 (en) | 2021-01-15 | 2022-07-21 | Beckley Psytech Limited | Ergoline analogues |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| GB202306256D0 (en) * | 2023-04-27 | 2023-06-14 | Beckley Psytech Ltd | 5-Methoxy-N,N-Dimethyltryptamine Formulations |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2026078143A1 (en) | 2024-10-09 | 2026-04-16 | GH Research Ireland Limited | Combinations of 5-meo-dmt with antidepressants for treating depression |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018195455A1 (en) * | 2017-04-20 | 2018-10-25 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| EP3713568A1 (en) * | 2017-10-26 | 2020-09-30 | Consejo Superior de Investigaciones Cientificas (CSIC) | Combination product for the treatment of neurological and/or psychiatric disorders |
| AU2020225766B2 (en) * | 2019-02-22 | 2025-10-30 | GH Research Ireland Limited | Compositions comprising 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for use in treating mental disorders |
| EA202192318A1 (ru) | 2019-02-22 | 2021-12-21 | Гх Рисерч Айрленд Лимитед | 5-метокси-n,n-диметилтриптамин (5-meo-dmt) для лечения депрессии |
| JP2022529781A (ja) * | 2019-04-17 | 2022-06-24 | コンパス パスファインダー リミテッド | サイロシビンによるうつ病及び他の様々な障害の治療 |
| EP4084791B1 (en) * | 2020-02-18 | 2024-12-18 | Gilgamesh Pharmaceuticals, Inc. | Specific tryptamines for use in the treatment of mood disorders |
| WO2021216489A1 (en) * | 2020-04-20 | 2021-10-28 | Lobe Sciences Ltd. | Methods for treating mild traumatic brain injury, post traumatic stress disorder and mild traumatic brain injury |
| KR20230024378A (ko) * | 2020-06-12 | 2023-02-20 | 벡클리 싸이테크 리미티드 | 5-메톡시-n, n-디메틸트립타민의 벤조에이트 염을 포함하는 조성물 |
| US11406619B2 (en) * | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| WO2022189662A1 (en) * | 2021-03-12 | 2022-09-15 | Alvarius Pharmaceuticals Ltd. | Compositions and methods for treating addictions comprising 5-meo-dmt |
| US11602521B2 (en) * | 2021-04-26 | 2023-03-14 | ATAI Life Sciences AG | N,N-dimethyltryptamine compositions and methods |
| WO2023028086A1 (en) * | 2021-08-23 | 2023-03-02 | Gilgamesh Pharmaceuticals, Inc. | Combinations of peripheral 5-ht2a receptor antagonists and central 5-ht2a receptor agonists |
| EP4448488A2 (en) * | 2021-12-13 | 2024-10-23 | Beckley Psytech Limited | Benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
-
2023
- 2023-03-27 KR KR1020247035719A patent/KR20250005177A/ko active Pending
- 2023-03-27 CA CA3255709A patent/CA3255709A1/en active Pending
- 2023-03-27 CA CA3255654A patent/CA3255654A1/en active Pending
- 2023-03-27 JP JP2024557757A patent/JP2025512866A/ja active Pending
- 2023-03-27 CN CN202380042750.2A patent/CN119255799A/zh active Pending
- 2023-03-27 EP EP23717032.9A patent/EP4499072A1/en active Pending
- 2023-03-27 US US18/851,294 patent/US20250213528A1/en active Pending
- 2023-03-27 JP JP2024557761A patent/JP2025511084A/ja active Pending
- 2023-03-27 IL IL315905A patent/IL315905A/en unknown
- 2023-03-27 WO PCT/EP2023/057878 patent/WO2023186831A1/en not_active Ceased
- 2023-03-27 IL IL315892A patent/IL315892A/en unknown
- 2023-03-27 CN CN202380037532.XA patent/CN119278036A/zh active Pending
- 2023-03-27 JP JP2024557206A patent/JP2025510294A/ja active Pending
- 2023-03-27 US US18/851,301 patent/US20250235427A1/en active Pending
- 2023-03-27 IL IL315904A patent/IL315904A/en unknown
- 2023-03-27 CN CN202380042391.0A patent/CN119255798A/zh active Pending
- 2023-03-27 KR KR1020247035763A patent/KR20250005184A/ko active Pending
- 2023-03-27 US US18/851,336 patent/US20250213531A1/en active Pending
- 2023-03-27 IL IL315901A patent/IL315901A/en unknown
- 2023-03-27 EP EP23717037.8A patent/EP4499077A1/en not_active Withdrawn
- 2023-03-27 US US18/851,362 patent/US20250213534A1/en active Pending
- 2023-03-27 KR KR1020247035707A patent/KR20250005175A/ko active Pending
- 2023-03-27 AU AU2023244447A patent/AU2023244447A1/en active Pending
- 2023-03-27 KR KR1020247035654A patent/KR20240167878A/ko active Pending
- 2023-03-27 EP EP23717041.0A patent/EP4499081A1/en not_active Withdrawn
- 2023-03-27 AU AU2023246681A patent/AU2023246681A1/en active Pending
- 2023-03-27 AU AU2023244453A patent/AU2023244453A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057871 patent/WO2023186824A1/en not_active Ceased
- 2023-03-27 CN CN202380036934.8A patent/CN119546298A/zh active Pending
- 2023-03-27 WO PCT/EP2023/057874 patent/WO2023186827A1/en not_active Ceased
- 2023-03-27 WO PCT/EP2023/057885 patent/WO2023186837A1/en not_active Ceased
- 2023-03-27 KR KR1020247035657A patent/KR20250005173A/ko active Pending
- 2023-03-27 AU AU2023246773A patent/AU2023246773A1/en active Pending
- 2023-03-27 US US18/851,316 patent/US20250213530A1/en not_active Abandoned
- 2023-03-27 JP JP2024557207A patent/JP2025510295A/ja active Pending
- 2023-03-27 CA CA3255652A patent/CA3255652A1/en active Pending
- 2023-03-27 JP JP2024557197A patent/JP2025510913A/ja active Pending
- 2023-03-27 US US18/851,349 patent/US20250213533A1/en active Pending
- 2023-03-27 EP EP23717038.6A patent/EP4499078A1/en active Pending
- 2023-03-27 CA CA3255329A patent/CA3255329A1/en active Pending
- 2023-03-27 AU AU2023246548A patent/AU2023246548A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057875 patent/WO2023186828A1/en not_active Ceased
- 2023-03-27 EP EP23717045.1A patent/EP4499085A1/en active Pending
- 2023-03-27 KR KR1020247035759A patent/KR20250005182A/ko active Pending
- 2023-03-27 US US18/851,311 patent/US20250213529A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057879 patent/WO2023186832A1/en not_active Ceased
- 2023-03-27 CA CA3255338A patent/CA3255338A1/en active Pending
- 2023-03-27 IL IL315903A patent/IL315903A/en unknown
- 2023-03-27 EP EP23717413.1A patent/EP4499089A1/en active Pending
- 2023-03-27 CN CN202380035882.2A patent/CN119156212A/zh active Pending
- 2023-03-27 CA CA3255640A patent/CA3255640A1/en active Pending
- 2023-03-27 KR KR1020247035720A patent/KR20250005178A/ko active Pending
- 2023-03-27 EP EP23717034.5A patent/EP4499074A1/en active Pending
- 2023-03-27 AU AU2023244449A patent/AU2023244449A1/en active Pending
- 2023-03-27 JP JP2024557208A patent/JP2025510296A/ja active Pending
- 2023-03-27 IL IL315900A patent/IL315900A/en unknown
- 2023-03-27 WO PCT/EP2023/057868 patent/WO2023186821A1/en not_active Ceased
- 2023-03-27 AU AU2023242439A patent/AU2023242439A1/en active Pending
- 2023-03-27 IL IL315895A patent/IL315895A/en unknown
- 2023-03-27 WO PCT/EP2023/057845 patent/WO2023186808A1/en not_active Ceased
- 2023-03-27 WO PCT/EP2023/057828 patent/WO2023186798A1/en not_active Ceased
- 2023-03-27 US US18/851,329 patent/US20250170099A1/en active Pending
- 2023-03-27 CA CA3255511A patent/CA3255511A1/en active Pending
- 2023-03-27 EP EP23717044.4A patent/EP4499084A1/en active Pending
- 2023-03-27 JP JP2024557199A patent/JP2025510914A/ja active Pending
- 2023-09-27 US US18/373,914 patent/US20240115550A1/en active Pending
- 2023-09-27 US US18/373,904 patent/US20240115549A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL315902A (en) | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of psychomotor retardation | |
| IL285537A (en) | 5-Methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in the treatment of depression | |
| IL315903A (en) | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of cognitive dysfunction | |
| IL285539A (en) | Preparations containing 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in the treatment of mental disorders | |
| IL288617A (en) | Medical preparations containing partially or fully deuterated n,n-dimethyltryptamine compounds | |
| NZ795865A (en) | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine | |
| EP4054668A4 (en) | HEMODIALYSIS SYSTEM WITH DIALYSATE GENERATOR | |
| BR112018067784A2 (pt) | regime de dosagem para o tratamento de exacerbações agudas de condições inflamatórias | |
| IL315894A (en) | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE for the treatment of postpartum depression | |
| PH12016502235A1 (en) | Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine | |
| CA3281369A1 (en) | 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression | |
| CA3295590A1 (en) | Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) | |
| AU2023902197A0 (en) | Treatment for tinnitus | |
| IL287529B (en) | A pharmaceutical combination that includes trazodone for the treatment of neuropathic pain | |
| AU2019904694A0 (en) | Plasma water treatment | |
| HK40081986A (en) | Crispr/cas9 system for multistrain hiv-1 treatment | |
| PL4010043T3 (pl) | Proteza komory serca i związany z nią układ wspomagania serca | |
| AU2017900496A0 (en) | Compounds for Enhancing the Permeation of Active Pharmaceutical Ingredients through Skin |